Payment overview · 2025
General Payments
$228.37
11 reported records · 7 companies
Healthcare provider profile · identity verified
Rita Schmid, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH BEND, IN · NPI 1306057724
Verified facts
What the public records show
CMS Open Payments records show Rita Schmid, M.D. received $228.37 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.86 | 42.4% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.20 | 12.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.67 | 12.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.10 | 9.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.20 | 8.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.14 | 7.1% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $15.20 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.37 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.52 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 861 | 199 |
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 204 |
| Losartan Potassium | Losartan Potassium | 493 | 125 |
| Lisinopril | Lisinopril | 484 | 129 |
| Simvastatin | Simvastatin | 391 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 115 |
| Alendronate Sodium | Alendronate Sodium | 344 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 84 |
| Omeprazole | Omeprazole | 227 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 64 |
| Metformin Hcl | Metformin Hcl | 207 | 50 |
| Gabapentin | Gabapentin | 162 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 41 |
| Sertraline Hcl | Sertraline Hcl | 150 | 42 |
| Furosemide | Furosemide | 149 | 36 |
| Trazodone Hcl | Trazodone Hcl | 143 | 46 |
| Synthroid | Levothyroxine Sodium | 125 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Metformin Hcl Er | Metformin Hcl | 102 | 32 |
| Tramadol Hcl | Tramadol Hcl | 97 | 31 |
| Alprazolam | Alprazolam | 94 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 27 |
| Atenolol | Atenolol | 89 | 26 |
| Ozempic | Semaglutide | 87 | 22 |
| Meloxicam | Meloxicam | 84 | 31 |
| Prednisone | Prednisone | 80 | 23 |
| Bupropion Xl | Bupropion Hcl | 79 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Glipizide Er | Glipizide | 77 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 30 |
| Allopurinol | Allopurinol | 71 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 20 |
| Lovastatin | Lovastatin | 70 | 21 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 16 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 16 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Eliquis | Apixaban | 52 | 15 |
| Carvedilol | Carvedilol | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 15 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Famotidine | Famotidine | 43 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 14 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Estradiol | Estradiol | 38 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 16 |
| Primidone | Primidone | 32 | 11 |
| Valsartan | Valsartan | 32 | 14 |
| Azithromycin | Azithromycin | 31 | 29 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Finasteride | Finasteride | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.37 · 11 records | Novo Nordisk Inc | AZUR CX DETACHABLE, EVENITY, INSPIRE, Omnipod, PENMENVY, PROLIA, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error